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Abstract
Background:
Knowledge of the natural history of human papillomavirus (HPV), in particular the role of im-
munity, is crucial in estimating the (cost-) effectiveness of HPV vaccination and cervical
cancer screening strategies, because naturally acquired immunity after clearing an infection
may already protect part of the risk population against new HPV infections.
Methods:
We used STDSIM, an established stochastic microsimulation model, quantified to the Neth-
erlands. We explored different assumptions regarding the natural history of HPV-16 and
HPV-18, and estimated the transmission probabilities and durations of acquired immunity
necessary to reproduce age-specific prevalence.
Results:
Amodel without acquired immunity cannot reproduce the age-specific patterns of HPV.
Also, it is necessary to assume a high degree of individual variation in the duration of infec-
tion and acquired immunity. According to the model estimates, on average 20% of women
are immune for HPV-16 and 15% for HPV-18. After an HPV-16 infection, 50% are immune
for less than 1 year, whereas 20% exceed 30 years. For HPV-18, up to 12% of the individu-
als are immune for less than 1 year, and about 50% over 30 years. Almost half of all women
will never acquire HPV-16 or HPV-18.
Conclusions:
Acquired immunity likely plays a major role in HPV epidemiology, but its duration shows
substantial variation. Combined with the lifetime risk, this explains to a large extent why
many women will never develop cervical cancer.
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Introduction
Infection with human papillomavirus (HPV) is a necessary cause for developing cervical cancer
[1], the fourth most common cancer among women worldwide [2]. HPV is one of the most prev-
alent sexually transmitted infections (STI) [3,4], and over 118 different types have been identified
[5]. At least 14 of these are considered high-risk types for cervical cancer due to their oncogenic
nature after progressing for a longer period of time [6]. However, most HPV infections clear nat-
urally. In the Netherlands, HPV prevalence in the general population (among women with nor-
mal cytology) was estimated to be 3.9% in 2010, with a peak in younger women [7].
The bivalent vaccine Cervarix offers protection against HPV-16 and HPV-18, which ac-
count for 70–76% of the cervical cancers [8]. Cervarix was introduced in the Netherlands in
2009 for 12-year old girls with a catch-up campaign for girls aged 13–16 years, with a modest
vaccine uptake of only 50% [9]. The vaccine was implemented in the national immunization
program in 2010. A crucial factor in estimating the effect of vaccination is naturally acquired
immunity, yet little is known about its degree and duration [10]. Understanding the transmis-
sion and immunity mechanisms of HPV is essential to adequately predict the (cost-)effective-
ness of HPV vaccinations and cervical cancer screening strategies.
Several mathematical models have been developed to study the spread of HPV and immuni-
ty processes responsible for clearing an HPV infection [11–17]. Some of these models are de-
terministic [13,14,17], and may not properly account for the complexity of transmission
through sexual networks [18]. Also, only HPV prevalence data of limited age ranges are used
[16], or the transmission probability was estimated per sexual partnership instead of per sexual
contact [11,13,14]. An exception is the study by Burchell et al. (2006), who estimated the medi-
an transmission probability at 40% per sex act, but ranging from a lower limit of 5% to an
upper limit of 100% [15]. This wide range indicates that further research on the transmission
probability per sexual contact is necessary, ideally by using more detailed data.
We explored the transmission dynamics of HPV-16 and HPV-18, especially regarding the
process of acquired immunity, by reproducing the age patterns of type-specific HPV preva-
lence in the Netherlands [19,20], using the established stochastic microsimulation model
STDSIM. This model has been used extensively for heterosexual transmission and control of
HIV and other STIs in African settings [21–23]. In the current study, we quantified the model
to a Western setting for the first time. The transmission of chlamydia ([24], personal commu-
nication), of which more is known regarding its natural history, has been included in the
model to validate our model fit of sexual behavior.
Methods
STDSIM and its quantification to the Netherlands
STDSIM simulates the life course of individuals in a dynamic network of heterosexual contacts,
in which STIs, such as HPV, can spread. Each individual has its own characteristics that are ei-
ther constant (e.g., date of birth and sex) or subject to change (e.g., number of sexual partners,
infection status). Events are determined by probability distributions, and can lead to new
events (e.g., a birth leads to a future event of becoming sexually active) or a cancellation of fu-
ture events (e.g., a death cancels all scheduled events concerning sexual activity or STI trans-
mission for this person and to or from his/her partner). More information on the model
structure can be found in the S1A Supporting Information.
We first used generally available information to quantify our model regarding demography
and sexual behavior. Age- and sex-specific life expectancy and migration data [25] and age-
specific fertility rates [25,26] were used to quantify STDSIM such that it represents the Dutch
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demography. To model the sexual network structure, we used data from three national sexual
health surveys [27–29]. We then simulated the transmission of chlamydia. Chlamydia is a
short-lasting STI that is common among heterosexuals in the Netherlands, and was included
to validate the level of risk behavior in the model. A detailed description of the model quantifi-
cation for the Dutch setting and the transmission and natural history of chlamydia can be
found in S1B-S1D Supporting Information.
Transmission and natural history of HPV
We simulated the transmission of HPV-16 and HPV-18. We assumed equal transmission
probabilities per sexual contact for male-to-female and female-to-male transmission
[13,15,17]. The transmission of both HPV types is independent given individual sexual risk be-
havior, and HPV transmission parameters were calibrated to make the model fit the observed
age- and type-specific HPV prevalences.
Two important aspects distinguish the transmission of HPV from other STIs in our model.
First, transmission can also occur through genital skin [30], and previous research shows no as-
sociation between condom use and HPV acquisition risk [31]. Therefore, we assumed that con-
doms do not have a protective effect against HPV, though they do protect against chlamydia.
Second, we assumed that women who have had a hysterectomy cannot acquire an HPV infec-
tion, similar to other modeling studies [13,14]. We used age-specific data to model the fraction
of women in the population who have had a hysterectomy [32]. In the model, women clear an
existing HPV infection immediately after a hysterectomy, and are considered immune for fu-
ture HPV infections.
We further assumed that the durations of infection and acquired immunity follow aWeibull
distribution. The Weibull distribution is a continuous probability distribution, defined by a
shape and scale parameter. If the shape parameter is set to 1, the distribution reduces to the ex-
ponential distribution. The shape parameters were varied with pre-set values of 0.25, 0.50, 1, 2
and 4. This allowed us to explore whether large (small shape parameter) or little (high shape
parameter) individual variation in the average duration of infection and acquired immunity
would be consistent with the available data.
The mean duration of an HPV infection in women was based on the studies of Goodman
et al. [33] and Trottier et al. [34], which measured type-specific time to clearance of an incident
infection in women with normal cytology within a large age range. Together, these studies re-
sulted in a total sample size of 966 women aged 18–85 years. We first transformed the median
durations reported by Goodman et al. [33] into mean durations, depending on the shape pa-
rameter of the Weibull distribution assumed. A weighted average of these results and mean du-
rations as reported in Trottier et al.[34] was then used as the mean durations for each HPV-
type in our model (S3 Table). To obtain mean infection durations in men, we again trans-
formed median durations based on the HPV in Men (HIM) Study of Giuliano et al. [35], which
included 1159 men aged 18–70 years.
In the base case analysis, we assumed that everyone acquires full immunity for some (Wei-
bull distributed) time immediately after clearing an infection. During this period, an individual
cannot acquire a new HPV infection, irrespective of whether this is due to the development of
antibodies or other components of the adapted immune system. We varied the immunity dura-
tion from no immunity to effectively lifelong, and the transmission probability from 0% to
100%, to find parameter values that made the model most accurately reproduce the observed
HPV prevalence trends with age (see section “Optimizing HPV parameters”). In addition, we
assumed an alternative mechanism for acquired immunity based on the history of HPV infec-
tions, for which the methods and results are documented in S1E Supporting Information.
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We used data on age-specific prevalence of high-risk HPV infections among women in the
Netherlands from the POBASCAM study [20]. The POBASCAM study is a population-based
randomized controlled trial (recruitment of women from 1999–2002) on the implementation
of high-risk HPV testing in cervical screening, including 21,950 Dutch women between the
ages of 29–61 years [20]. We added data from a cross-sectional study (2007) among women
aged 18–29 years representative for the general population in the Netherlands, to include HPV
prevalence data of young women outside the screening age [19]. Both studies only measured
the overall high-risk HPV prevalence. Based on Coupé et al., who also used POBASCAM data
[36], we calculated the age-specific fractions of each HPV type within the overall prevalence,
and applied these fractions to the above mentioned data to obtain the type-specific HPV preva-
lence (S4 Table). We assumed a 94% HPV test sensitivity [37,38].
Optimizing HPV parameters
We performed a grid search to determine combinations of transmission probabilities and
mean duration of acquired immunity (Weibull distributed) for each HPV-type, and the 5 pre-
set shape parameters of the Weibull distributions of the durations of infection and acquired im-
munity that result in the best fit to the type- and age-specific HPV prevalence. For each param-
eter combination, we ran the model 100 times. The best fit was based on the binomial log-
likelihood of the observed prevalence data and model estimates summed over the age catego-
ries. The log-likelihood ratio is the difference between log-likelihoods of two different models
[39]. To compare models, we performed likelihood ratio tests using the log-likelihood ratio
times-2, which is approximately chi-squared distributed.
For the combinations of Weibull shapes with the best fit, we used a regression model of the
transmission probability and acquired immunity duration as a metamodel [39,40]. First, we fit-
ted the log-likelihoods of the grid to a second order polynomial regression model, as has been
done by Fischer et al. [39]. We then determined the optimal parameter combination of the
transmission probability and acquired immunity duration, as well as 95% confidence intervals
(CIs). We ran the model with this optimal parameter combination 1000 times, to precisely de-
termine the predicted average age- and type-specific HPV prevalence. Finally, we performed a
chi-squared test summed over the age categories to determine the goodness-of-fit of our model
compared to the observed HPV prevalence.
Finally, we used the optimal model to estimate the age-specific proportion of women who
are immune for HPV-16 and HPV-18, respectively. We accounted for uncertainty in the type-
specific transmission probability and the duration of acquired immunity by re-running the
model with 200 alternative parameter combinations [23]. We randomly sampled combinations
from the 95% CIs of the estimated transmission probabilities and immunity durations, and ac-
cepted them if the resulting age-specific HPV prevalence did not differ significantly from the
optimal model predictions. Uncertainty ranges for the proportion of women with acquired im-
munity were subsequently obtained by taking the 5th lowest value as lower bound and 5th high-
est value as upper bound for each age group.
Results
Our model is able to accurately simulate the Dutch population (Fig. 1A), number of recent
partners for men (Fig. 1B, left bars) and age difference in relationships (Fig. 1C and 1D). The
model does show a larger proportion of women with 2 or more recent partners than reported
in the surveys (Fig. 1B, right bars). However, especially for women, it is well-known that social
desirability bias in self-reported sexual behavior often results in underreporting of the number
of current or recent partners to make a more favorable appearance [41,42]. The modeled
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Figure 1. Comparison of the model predictions with data of population composition, sexual behavior and chlamydia prevalence.Modeled
population composition per age group, compared to data of Statistics Netherlands [25] (A). Modeled number of partners in the last 6 months in men and
women aged 20–64 years, compared to data of 19–64 years old in Rutgers WPF [27,28] (B). Mean and standard deviations (sd) of age differences in
relationships, reported by male respondents (C) and female respondents (D). Modeled chlamydia prevalence of 15–29 years old compared to the data of Van
den Broek et al. (2012) [24] of 16–29 years old (E).
doi:10.1371/journal.pone.0116618.g001
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prevalence of chlamydia for both men and women is close to the observed prevalence levels
given by Van den Broek et al. ([24], personal communication; Fig. 1E).
Fig. 2 shows the best estimated HPV-16 and HPV-18 prevalence when assuming no immu-
nity, exponential distributions, and Weibull distributions. A model without acquired immunity
clearly cannot reproduce the age-specific patterns in the prevalence of HPV-16 and HPV-18
(Fig. 2). The prevalence is underestimated in women aged 25–33 years, while overestimated in
older age groups. For both HPV-types, it is also not sufficient to assume exponential distribu-
tions for the duration of infection and acquired immunity. While the best fitting model for
HPV-16 still deviates from the data for women aged 18–33 years (w2 (5) = 15.26, p =.009;
S1F Supporting Information, S5 Table), it provides a significantly better fit than the model
without immunity (w2 (4) = 43.88, p<.001), and the model with exponential distributions
(w2 (4) = 53.24, p<.001). This best fitting model had Weibull shape parameters of 0.50 and
0.25 for the duration of infection and immunity, respectively, corresponding with half of the
men and over 70% of women clearing their infection within 1 year (S3 Table). In this model,
Figure 2. Comparison of the observed and estimated age-specific HPV prevalence. The estimated prevalence is given by the best fitting models of the
different scenarios. These scenarios include no acquired immunity after clearing an infection (exponential distribution for the duration of infection);
exponentially distributed durations; Weibull distributed durations. (A) shows the results for HPV-16; (B) for HPV-18.
doi:10.1371/journal.pone.0116618.g002
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almost 50% of the individuals are no longer immune 1 year after clearing the infection (S6
Table). Still, about 20% have an estimated duration of acquired immunity that lasts longer than
30 years. The corresponding estimated transmission probability is 6.9% per sexual contact
(95% CI: 5.4; 8.6).
For HPV-18, we found similar individual variation in the infection duration compared to
HPV-16. The corresponding Weibull shape of 0.50 suggests that 62% of men and 69% of
women clear their infection within 1 year (S3 Table). For almost 15% of men and over 9% of
women, infection lasts longer than 4 years. The model with immunity fits the data significantly
better than the model without immunity, in which the prevalence is underestimated in women
aged 25–33 years and overestimated in women aged 34+ years (Fig. 2B, S5 Table). The model
with Weibull distributions fits the data better than with exponential distributions, which shows
similar deviations as the model without immunity (Fig. 2B, S5 Table). Fits using Weibull
shapes of 0.50, 1, 2, and 4 are comparable, indicating that the shape parameter of the duration
of immunity is less important for HPV-18 compared to HPV-16. These shape parameters cor-
respond with 42–50% of the individuals having an estimated duration of acquired immunity
longer than 30 years, while only 0–12% is immune for less than 1 year after clearing the infec-
tion (S6 Table). Corresponding estimated transmission probabilities for the model range from
6.7% (95% CI: 5.4; 8.3) to 9.0% (95% CI: 5.7; 13.0) per sexual contact. This model shows no sig-
nificant deviations from the observed HPV-18 prevalence (S5 Table).
The best fitting model for HPV-16 and HPV-18 suggests that approximately half of the
women in the model will have an HPV-16 infection in their lifetime (Fig. 3A), and 25% an
HPV-18 infection (Fig. 3B). About 46% of women will never acquire either an HPV-16 or
HPV-18 infection in our model (Fig. 3C). The proportion of women who are immune to HPV-
16 is higher than HPV-18, peaking at 22% of women aged 30–39 years for HPV-16 (Fig. 4A)
and 15% of women aged 30–44 years for HPV-18 (Fig. 4B).
Discussion
In this study we quantified STDSIM to a high-income country for the first time. The model
was able to accurately replicate the Dutch population and sexual network. Our estimates indi-
cate that including a mechanism of acquired immunity is essential to adequately explain the
age patterns of HPV prevalences in the Netherlands. Also, our model suggests that there is
large individual variation in the duration of infection and acquired immunity. This is especially
the case for HPV-16, for which, in our model, 50% of the individuals are immune only for less
than a year after clearing an infection, yet 20% for longer than 30 years. For HPV-18, a higher
proportion will develop long lasting acquired immunity.
Our finding that large individual variation exists in naturally acquired immunity is consis-
tent with Mikolajczyk et al. [43], who concluded that the observed distribution of antibody ti-
ters reflects individual differences in immune response. We found that, especially for HPV-16,
most women only become immune for a relatively short period of time (less than 1 year) after
clearing an infection. This concurs with earlier findings of an association between re-infections
and sexual activity [44], likely due to rapidly waning immunity after clearing an infection in
some women. In addition, studies found that only 40–60% of previously infected individuals
have detectable antibodies shortly after an infection [45,46], further suggesting that many
women were immune for a short period of time or not at all. Surprisingly, our results suggest
that acquired immunity lasts longer than 30 years for about half of the people after clearing an
infection of HPV-18, whereas the proportion of people with acquired immunity less than 1
year is minimal, ranging from 0.07% to 12% in the best fitting model. Baussano et al. [47] also
found in his model that a larger proportion of individuals developed lifelong immunity for
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Figure 3. Predicted cumulative number of HPV-16 (A), HPV-18 (B), and HPV-16/-18 (C) infections in
women. The proportion of women with no lifetime infections slightly increased in women aged 65+ compared
to women aged 50–64 years. This results from a cohort effect due to a combination of historical data on fertility
rates and timing of an increase in migration (1965), and will only have a minimal effect on our estimates.
doi:10.1371/journal.pone.0116618.g003
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Figure 4. The distribution of acquired immunity in the best fitting model for HPV-16 (A) and HPV-18 (B). Bars reflect uncertainty ranges (see Methods).
doi:10.1371/journal.pone.0116618.g004
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HPV-18 compared to HPV-16. It could be that, for those developing naturally occurring anti-
bodies, the amount of protection may be different between HPV-16 and HPV-18 [48]. Possible
reasons behind these contrasting findings should follow from clinical research.
We also found that some degree of individual variation must be assumed in the duration of
infection. This variation in infection duration could to some extent be attributable to latent un-
detectable infections and might be difficult to measure in observational studies. While some in-
fections might appear as two separate infections in observational studies, they could be an
ongoing long-term infection that might have been latent during follow-up visits. On the other
hand, very short infections might not be detected since they could fall between follow-up visits
[49].
Our model for HPV-18 has a good model fit and does not deviate significantly from the ob-
served prevalence data. For HPV-16, the model shows a slightly worse fit to the data. In partic-
ular, it overestimates the HPV-16 prevalence for women aged 18–24 years, and shows a small
underestimation for women aged 25–33 years. This may be due to dynamics in natural history
specific to HPV-16 that are difficult to capture in models. However, the differences are
relatively small and are unlikely to influence our results.
Our study has some limitations. First, we ignored effects as a result of cervical cancer and
cervical cancer screening on HPV transmission. Infections only clear naturally in our model
and not through the removal of high-grade lesions. However, the majority of infections does
not end by treatment of cervical neoplasia. Hence, the underestimation of the transmission
probability per sexual contact is likely minimal. Second, the Weibull shapes in our model for
the duration of infection and acquired immunity are only fitted using pre-set parameter values.
Limited data did not allow a more precise assessment of shapes. Thus, individual variation in
reality could somewhat differ from the best fitting model parameters chosen in our study.
Third, we assumed that the durations of infection and immunity are randomly drawn. It could
be that these durations depend on individual characteristics, such as age, history of HPV infec-
tions, or individual factors related to the immune system. Fourth, we did not incorporate
cross-protection of immunity between HPV-16 and HPV-18 in our model. Clinical trials have
shown that the HPV-specific vaccines protect to some extent against other HPV-types as well
[50], indicating that cross-protection may also exist in naturally acquired immunity. However,
the extent of cross protection of acquired immunity against HPV-16 and HPV-18 is currently
unknown, and we have therefore not incorporated it in our model. A particular strength of our
study is that we did not rely on HPV prevalence data based on opportunistic cervical screening
for younger women (outside of the age range of the Dutch cervical cancer screening program).
A representative sample was used instead, leading to more reliable age-specific patterns which
are crucial in understanding the natural history of HPV.
Our model suggests that the lifetime risk of acquiring an HPV-16 or HPV-18 infection for
women is about 50%. This is nearly as high as the risk of only HPV-16, indicating that many
women with an HPV-18 infection will also acquire an HPV-16 infection in their lifetime. In
our model, acquired immunity for HPV-16 and HPV-18 infections peaks at 22% and 15% of
women respectively, and especially those with long-term acquired immunity will benefit less
from vaccination as they are already protected naturally. In addition, women who develop im-
munity are the women with the highest risk, given their history of an HPV infection. Therefore,
even though HPV vaccination will certainly decrease individual risks of cervical cancer, many
women would not really need it since they will never acquire an HPV-16 or HPV-18 infection
during their lifetime, and others are already protected because of naturally acquired immunity
after clearing an infection. Clearly, vaccines will be most effective when targeted at young
women, at an age before starting sexual relationships and being exposed to HPV for the first
time. As the indirect effects of vaccination depend on the sexual network, acquired immunity,
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vaccine coverage, and target groups, a model is essential to further study the (cost-)effective-
ness and optimal delivery strategies of HPV vaccination in preventing cervical cancer.
We also explored an alternative mechanism for acquired immunity after clearing an HPV-
16 or HPV-18 infection (S1E Supporting Information). In this mechanism, women are not
fully immune for variable duration, yet their susceptibility to re-infection reduces cumulatively
after each infection. For both HPV-types, we found similar individual variation in infection du-
ration and transmission probabilities compared to the base case mechanism. It was again nec-
essary to assume acquired immunity after clearing an infection. Also under this mechanism,
about half of the women will never acquire HPV-16 or -18. The alternative mechanism did
show a worse fit to the observed prevalence data.
In conclusion, we show that, using a mathematical model, acquired immunity likely plays a
major role in HPV epidemiology. While our model suggests that most people are only immune
for a short period of time after clearing an HPV-16 infection, acquired immunity is long-term
for most people after clearing an HPV-18 infection. The proportion of women being immune
for HPV-16 and HPV-18 and lifetime risk for an HPV-16 and HPV-18 infection already ex-
plains to a large extent why most women will never develop cervical cancer.
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